RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced that abstracts featuring lorundrostat clinical data from both Phase 2 and Phase 1 studies have been selected for a moderated poster presentation and poster presentation at the American College of Cardiology’s 72nd Annual Scientific Session together with the World Congress of Cardiology (ACC.23/WCC), which is scheduled to take place in New Orleans, LA, on March 4-6, 2023.
Mineralys Poster Details:
Moderated Poster Title: | Highly Effective Blood Pressure Lowering with lorundrostat, a New Aldosterone Synthase Inhibitor, in Individuals with Obesity and RAAS Dysregulation |
Presenter Name: | David Rodman, MD, FAHA |
Session Title: | Treating the Whole Patient including Comorbidities |
Presentation Number: | 1029-05 |
Presentation Time and Date: | 3:15 p.m. – 3:25 p.m. CT on Saturday, March 4, 2023 |
Session Location: | Heart Failure and Cardiomyopathies Moderated Poster Theater 9, Hall F |
Poster Presentation Title: | First-In-Human Study of lorundrostat, a Potent and Highly Selective Aldosterone Synthase Inhibitor |
Presenter Name: | David Rodman, MD, FAHA |
Session Title: | Heart Failure and Cardiomyopathies: Clinical Science 11 |
Presentation Number: | 1560-160 |
Presentation Time: | 12:45 p.m. – 1:30 p.m. CT on Sunday, March 5, 2023 |
Session Location: | Poster Hall, Hall F |
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.